Are intervention effects on fruit and vegetable intake maintained after 48 months of follow-up? A randomised controlled community trial.

Public Health NutrOct 26, 2026 (epub)

Maria Cecília Ramos de Carvalho, Mariana Souza Lopes, Patrícia Pinheiro de Freitas et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomised controlled community trial assessed whether increases in fruit and vegetable (FV) intake after a 7-month transtheoretical model-based intervention were maintained among users of a Brazilian primary health care service who had positive intake changes at 12 months. At 36 months, fruit intake had decreased by 54.4 g/d and vegetable intake by 38.5 g/d; adjusted analyses found similar decreases in the intervention and usual-care groups. At 48 months, intake increases were also similar between groups, indicating that the intervention’s initial changes were not maintained.

Key findings

  • At 36 months, fruit intake decreased by 54.4 g/d and vegetable intake by 38.5 g/d.
  • Adjusted analyses found similar FV intake decreases in intervention and control participants at 36 months.
  • At 48 months, fruit intake increased by 6.9 g/d and vegetable intake by 23.4 g/d; increases were similar between groups.

Why it matters

The findings suggest that early improvements in dietary intake after a community intervention may not persist over the long term. Evaluations of health-promotion programmes should therefore assess outcomes beyond the initial intervention period and consider whether continued support is needed to sustain behavioural changes.

What to keep in mind

The analysis included participants who had positive intake changes at 12 months, limiting its applicability to all trial participants.

Source

Published in Public Health Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Preventive Medicine / Public Health

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.